New hope: hepatitis c drugs after liver cancer treatment
NCT ID NCT02771405
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether interferon-free drug combinations can cure hepatitis C in 150 people who had been successfully treated for liver cancer. Participants took pills like sofosbuvir and ribavirin for 12 weeks. The main goal was to see if the virus stayed undetectable 12 weeks after treatment, and to check for any cancer return.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Sofosbuvir, Ribavirin, Simeprevir, Daclatasvir, Ledipasvir
What this could lead to
If successful, this could show that treating hepatitis C after liver cancer treatment reduces cancer recurrence and improves long-term outcomes.
What could go wrong
This is a completed Phase 3 trial, but results may not apply to all patients. There is a risk of virologic failure or cancer recurrence despite treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATITIS C, CHRONIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Amr Maged
Cairo, 11441, Egypt